Batm Advanced Communicat... Share Discussion Threads

[sandy789] 28/1/2021 12:21

My point is that i am guessing you are not turning this for 5p profit. So sell at 102 take your profit. On what basis do you value this company at 110 if you don't understand the medical business. I don't understand the business completely. However i do know that the company is operating in growth areas like 5g medical waste and testing for medical conditions. I haven't a clue what the value of the company is and i couldn't put a price on the shares. But i do know that Zvi has steered the company out of optical switches which is what attracted me in 1998 and into these growth areas making me a lot of money. I have a pretty good idea that the break up value of this company is over £400m so more than happy to hold. This is a serious business now and will follow the main market so play the footsie instead if you want to nickle and dime.

[wizzkid211] 28/1/2021 11:36

Sometimes in life when the whole market is painted red it takes balls to stay with quality share...

[doccash] 28/1/2021 11:26

Last year's results early March for hard numbers

Otherwise listen to Zvi last talk on proactive site All areas company progressing well

[car1pet] 28/1/2021 11:09

My problem with the share is the 2 very different businesses. I know nothing about the medical business so can't judge whether it is a good business or not. If the all the testing products are good why hasn't it gone gangbusters during the covid outbreak. I don't know the impact of vaccines on the business. I can see that testing will need to be required going forward but again if the products are good why aren't we seeing a pipeline of orders. I know a lot of posters are big fans of the company but I'm an investor in it to make money and I find it hard to judge the company.

[sandy789] 28/1/2021 10:15

I don't see your point. I wanted to sell at 1.50 and missed it. I also wanted to but at 80p and missed that as well.

[leewain] 28/1/2021 09:39

A bargain under £1.

[paulisi] 28/1/2021 09:30

Market makers have forced this down on no volume.For anyone panicking - hang on for the results end Feb/early Mar and the accompanying outlook statement.

[emeraldzebra] 28/1/2021 09:27

car1pet. No confidence in the 175p prediction from Investors chronicle then ? I am clinging on in small expectation but lots of hope......!

[car1pet] 28/1/2021 08:52

Annoying drop today I was just about to sell at 107. Most markets are down this morning coupled with yesterday's fall its over 2% down i think. I thought it might get to 110 but can't see it getting much higher. Plan to get out and watch from the sidelines

[paulisi] 26/1/2021 07:55

Price has held up well.I suspect we should get notification of when the final results will be published within the next week.Hopefully, it will advise that results are better than anticipated.

[wizzkid211] 22/1/2021 18:52

CAR1PET

The Group's COVID-19 antigen test has 4+1 gene discovery capability, including the S protein, compared with a market standard of one to three gene discovery. This enables it to provide more accurate results, reducing the risk of false positives and false negatives. The Group is now offering its 4+1 kit as its standard COVID-19 antigen test, which is being delivered to several private and government customers in Europe and other geographies.



BEING DELIVERED NOW IN EUROPE

[car1pet] 22/1/2021 18:01

If BATM has a product which can provide effective and accurate testing for all covid variants why are we not seeing orders going off the scale? In the UK there is much talk about lateral flow tests only being 50% accurate. If the BATM test is so good why isnt the UK buying millions of them? Patrick Vallance said today that he was talking to his counterpart in Israel about the virus. I'm puzzled that we hear from BATM about their test but no mention of the UK buying it. Am I missing something here.

[reeltime] 22/1/2021 16:56

Not sure if this has been posted befor.....

BATM Advanced Communications : confirms effectiveness of its COVID-19 test in diagnosing new strain of virus
01/19/2021 | 10:41am GMT

BATM confirms effectiveness of its COVID-19 test in diagnosing new strain of virus

COVID-19 tests effective in detecting the SARS-CoV-2 variant observed in the UK and elsewhere

BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, announces that its COVID-19 kit has been tested against the new SARS-CoV-2 variant - the virus that causes COVID-19 - that is being observed as rapidly spreading in the UK and elsewhere and the Group can confirm that it is effective in diagnosing this new strain.

The new SARS-CoV-2 variant, referred to as SARS-CoV-2 VUI 202012/01, is defined by multiple spike (S) protein mutations as well as mutations in other genomic regions. The Group, in partnership with Tor Vergata University, continually tests its kits against any mutation that is perceived to be clinically material to ensure its kits are accurately able to detect all known variants of COVID-19.

The Group's COVID-19 antigen test has 4+1 gene discovery capability, including the S protein, compared with a market standard of one to three gene discovery. This enables it to provide more accurate results, reducing the risk of false positives and false negatives. The Group is now offering its 4+1 kit as its standard COVID-19 antigen test, which is being delivered to several private and government customers in Europe and other geographies.

Dr Zvi Marom, CEO of BATM, said: 'I am pleased to confirm that our COVID-19 tests are effective in accurately detecting all COVID-19 variants, including in those infected with this latest mutation. Viruses constantly change through mutation and our diagnostics platform has been built on our recognition that we must always think of the future. As a result, we were able to rapidly develop COVID-19 tests in response to the outbreak and those kits have been designed to be effective against the emergence of new variants.'

Enquiries:

BATM Advanced Communications
Dr Zvi Marom, Chief Executive Officer
[phone]
Moti Nagar, Chief Financial Officer

[paulisi] 22/1/2021 12:20

Are vaccines the perfect solution? Read more: https://t.co/8uzLvoH1uB https://t.co/n8LRrB5uftBit more info on sputum test - more accurate than the lateral test.

[rawdeal1] 21/1/2021 18:35

Thank you Car1pet.

[car1pet] 21/1/2021 17:53

The 165k is an Uncrossing Trade (UT) this takes place at the end of the day and matches buys and sells, so its not a large single trade

[paulisi] 21/1/2021 17:06

Showing as 165k buy

[rawdeal1] 21/1/2021 16:52

Very big trade at the end. Anyone know whether it was a buy or sell .. ?

[fse] 20/1/2021 22:13

Thats a knock out video. Anyone invested in BATM really should watch it.
I can not imagine how any large or even medium size nursing or care home would not benefit from having one of these units in situ.
To say nothing about the other obvious users like airports and meat packing plants or any large corporate manufacturer...the list is endless and the benefits enormous . This is another win win situation for BATM and their clients.
Thats a lot of what I like about BATM medical and Telco that they offer solutions which actually save money and unnecessary wastage of time and resources.

[doccash] 19/1/2021 19:18

We have continued to receive strong interest in NFVTime, which we expect to increase with this broadening of the addressable market at a time when the adoption of cloud-based networking is expanding. We look forward to reporting on our progress.

Last line is hopeful for further news soon

[fse] 19/1/2021 18:27

technology-winners-for-the-new-normal/




[January 19, 2021]
Telco Systems Upgrades its NFVTime Edge Compute Management Solution for Public Cloud


MANSFIELD, Mass., Jan. 19, 2021 /PRNewswire/ -- Telco Systems, the leading provider of innovative SDN/NFV, CE 2.0, MPLS and IP solutions, today announced that the company has upgraded its NFVTime uCPE and Edge Compute solution to support public Cloud environments, including Amazaon Web Services (AWS) and Microsoft Azure.

As part of the upgrade, Telco Systems has completely rearchitectured its MANO (management and orchestration) to operate natively in public Clouds. This upgrade also includes full security and availability mechanisms for these platforms.

Telco Systems' new NFVTime uCPE and Edge Compute offering allows its telco and managed service provider customers to focus on expanding their portfolios of NFV-based services and generating new sources of revenue from their business customer segments. By running the NFVTime uCPE MANO solution in a public Cloud environment, service providers no longer need to spend valuable time and resources managing the IT and security issues that typically impact private Cloud environments.

Telco Systems reports that the company is receiving strong interest in its NFVTime uCPE offering for ublic Cloud environments from Tier 1 and 2 service providers in North America and Western Europe as well as small operators in emerging markets, especially across Asia and Africa. The company notes that the market opportunity for more resiliency, security and availability of a public Cloud MANO is accelerating the demand for its new NFVTime offering.





"The telecom market is discovering the beauty of the public Cloud," explained Ariel Efrati, CEO of Telco Systems. "Our exciting new uCPE offering for the public Cloud is attracting attention from forward thinking service providers around the world, accelerating its adoption and providing valuable new use cases for their enterprise customers."

NFVTime is an open plug-and-play virtualization suite. The solution provides a complete environment for quick service deployments with centralized management and orchestration. It features zero touch provisioning that ensures all new white box devices and third party VNFs are configured, up-to-date and fully operational within minutes.

[fse] 19/1/2021 17:28

Just looking at the NFVTime upgrade and the expansion of the potential client base by including Public networks is very significant. This could have some very profound implications albeit I have no specific idea as to the increase of the target area it has to be very large... guess we are set to find out.
Another one of Shores obtuse announcements. As you know Shore and BATM are joined at the hip so the one real positive about the announcement is that its come from the horses mouth so in that respect its encouraging news.

[doccash] 19/1/2021 12:53

In a note on Tuesday, analysts at house broker Shore Capital said BATM is "addressing large market opportunities demanding technology-based solutions" and is also "sustaining investment into its technology and client solutions with more positive developments to come".

"Strong underlying operating development is now being witnessed across both divisions in the Group with clients and partners keen to tap into BATM’s emerging technologies. We believe that the financial rewards are also becoming visible, with a return to the dividend list anticipated shortly reflecting a strong balance sheet. BATM is developing quickly across the Group and we look forward to further forecast upgrade potential, underpinning the strong performance of BATM’s stock", the broker added.

[paulisi] 19/1/2021 09:05

Nice bumpExpect more contract news for NFV rime